Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience

HIGHLIGHTS

  • who: Adrianna Spałek from the School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street, ‑, Katowice, Poland have published the article: Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience, in the Journal: (JOURNAL)
  • what: The aim of this study was to evaluate RUX efficacy and toxicity in a real-world setting. The authors report on the real -life data of RUX for advanced SR-aGVHD undergoing allo-HSCT in the center between years 2019 and 2021 . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?